Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Expires | Type | Strike | OI | Change | Percent |
---|---|---|---|---|---|
11/21/2025 | CALL | $25.00 | 23,291 | +7,077 | +43.65% |
09/19/2025 | PUT | $24.50 | 8,183 | +2,956 | +56.55% |
09/12/2025 | CALL | $25.00 | 12,707 | +2,733 | +27.40% |
10/03/2025 | CALL | $26.00 | 4,262 | +2,624 | +160.20% |
09/19/2025 | CALL | $25.00 | 39,347 | +2,362 | +6.39% |
09/18/2026 | PUT | $22.00 | 4,173 | +1,160 | +38.50% |
09/19/2025 | CALL | $25.50 | 10,118 | -263 | -2.53% |
09/19/2025 | CALL | $27.00 | 36,940 | -299 | -0.80% |
09/19/2025 | CALL | $28.00 | 16,362 | -302 | -1.81% |
09/19/2025 | CALL | $24.00 | 21,250 | -505 | -2.32% |
09/19/2025 | CALL | $26.00 | 38,689 | -545 | -1.39% |
09/12/2025 | PUT | $26.00 | 24,909 | -2,182 | -8.05% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Name | Pct Held | Shares | Total |
---|---|---|---|
Vanguard Total Stock Market Index Fund | 3.02% | 170.64M | 6.14B |
Vanguard 500 Index Fund | 2.30% | 129.76M | 4.67B |
Washington Mutual Investors Fund | 1.42% | 80.41M | 2.89B |
Fidelity 500 Index Fund | 1.09% | 61.54M | 2.21B |
SPDR S&P 500 ETF Trust | 1.08% | 60.77M | 2.19B |
American Balanced Fund | 1.00% | 56.61M | 2.04B |
Income Fund of America Inc | 0.93% | 52.68M | 1.9B |
iShares Core S&P 500 ETF | 0.89% | 50.1M | 1.8B |
Vanguard Index-Value Index Fund | 0.86% | 48.51M | 1.75B |
Vanguard Specialized-Health Care Fund | 0.86% | 48.32M | 1.74B |
Why BioNTech Stock Sank by More Than 7% Today
09/12 06:19 pm
The Motley Fool
Read moreQuestex’s Fierce Pharma Announces the 2025 Fierce Pharma Marketing Awards Winners
09/10 11:30 pm
GlobeNewswire Inc.
Read moreFDA Moves To Publicize Data On Pregnant Women's Covid Vaccine Side Effects
09/10 01:21 pm
Benzinga
Read moreHCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
09/09 08:00 am
GlobeNewswire Inc.
Read moreThe Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now
09/09 06:05 am
The Motley Fool
Read morePfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults
09/08 02:13 pm
Benzinga
Read moreThink It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.
09/07 11:14 am
The Motley Fool
Read moreIs Pfizer a Millionaire Maker?
09/07 09:30 am
The Motley Fool
Read moreDown 34%, Should You Buy the Dip on Viking Therapeutics?
09/05 04:10 am
The Motley Fool
Read moreAustralia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer
09/04 11:00 am
GlobeNewswire Inc.
Read moreMonoclonal Antibodies Therapeutics Market Size Projected to Reach USD 1,057.91 Billion by 2034
09/04 11:00 am
GlobeNewswire Inc.
Read moreSalesforce Posts 10% Revenue Gain in Q2
09/04 09:05 am
The Motley Fool
Read morePDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight
09/03 01:00 pm
GlobeNewswire Inc.
Read moreStomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - Novel Therapies, Increasing Demand for Affordable Treatments, and Favorable Reimbursement Scenario Position the Market for Strong Growth
09/03 04:49 am
GlobeNewswire Inc.
Read moreHealthcare Valuations Near Multi-Year Lows Suggest Risk–Reward Asymmetry
09/02 09:37 am
Investing.com
Read more3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever
09/02 03:21 am
The Motley Fool
Read moreAcne Medicine Market Size Projected to Reach USD 23.33 Billion by 2034
09/01 10:00 am
GlobeNewswire Inc.
Read moreEpinephrine Market to Size to Reach USD 5.74 Billion by 2032 as Demand for Emergency Allergy Treatments Surges – SNS Insider
09/01 09:00 am
GlobeNewswire Inc.
Read moreHealthcare Is Sickly but These Dividend Yields up to 7% May Still Have a Pulse
08/29 05:14 am
Investing.com
Read moreGlobal Pharmaceuticals Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight
08/27 01:00 pm
GlobeNewswire Inc.
Read morePfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
08/27 12:50 pm
GlobeNewswire Inc.
Read moreHuman Growth Hormone Market to Hit USD 18.25 Billion by 2032, Driven by Expanding Therapeutic Applications and Biotech Advances – SNS Insider
08/27 10:00 am
GlobeNewswire Inc.
Read moreBinge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize
08/27 08:00 am
GlobeNewswire Inc.
Read moreDyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic
08/27 04:59 am
GlobeNewswire Inc.
Read moreChronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma
08/27 04:50 am
GlobeNewswire Inc.
Read moreViking Therapeutics: What's Next?
08/26 06:15 am
The Motley Fool
Read moreGlobal Thyroid Gland Disorder Treatment Market to Increase at a Steady Growth Rate of ~3% by 2032 | DelveInsight
08/21 01:00 pm
GlobeNewswire Inc.
Read moreCytotoxic Drugs & HPAPI Manufacturing Market Industry Trends and Global Forecasts to 2035 | Over 140 Players Now Active in HPAPI & Cytotoxic Drug Contract Manufacturing
08/21 05:59 am
GlobeNewswire Inc.
Read moreUnderstanding the Nanomedicine Landscape: Key Players and Emerging Trends
08/21 04:38 am
GlobeNewswire Inc.
Read moreAscentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
08/20 07:57 pm
GlobeNewswire Inc.
Read moreQuestex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing
08/20 10:00 am
GlobeNewswire Inc.
Read moreLigand to Participate in September Investor Conferences
08/19 04:00 pm
GlobeNewswire Inc.
Read morePD-(L)1 Inhibitors Market Set to Surge During the Forecast Period (2025–2034) as Immuno-Oncology Therapies Gain Momentum | DelveInsight
08/18 01:00 pm
GlobeNewswire Inc.
Read more2 Top Dividend Stocks to Buy on the Dip
08/16 09:07 am
The Motley Fool
Read more3 Long-Term Dividend Buys You Can Get for Under $50
08/15 10:37 am
Investing.com
Read moreAfter a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?
08/15 07:15 am
The Motley Fool
Read moreLigand Announces Closing of Convertible Senior Notes Offering
08/14 04:00 pm
GlobeNewswire Inc.
Read moreCDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency
08/12 01:41 pm
Benzinga
Read moreMerck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
08/12 10:46 am
Benzinga
Read moreLigand Announces Pricing of $400 Million Convertible Senior Notes Offering
08/11 11:46 pm
GlobeNewswire Inc.
Read moreIf You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today
08/11 09:16 pm
The Motley Fool
Read morePfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock?
08/11 08:15 pm
The Motley Fool
Read moreLigand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
08/11 07:00 am
GlobeNewswire Inc.
Read more2 Beaten-Down Stocks to Buy and Hold
08/10 09:15 am
The Motley Fool
Read moreMeet the 7.3% Yield Dividend Stock That Could Soar in 2026
08/10 06:05 am
The Motley Fool
Read moreNxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
08/08 02:45 am
GlobeNewswire Inc.
Read moreCancer Cachexia Clinical Trial Pipeline Shows Potential with Active Contributions from 18+ Key Companies | DelveInsight
08/07 01:00 pm
GlobeNewswire Inc.
Read moreAscentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025
08/07 08:00 am
GlobeNewswire Inc.
Read more